The document discusses Embase indexing. It provides an overview of how Embase indexes drugs, diseases, and medical devices in depth using subheadings, trade names, manufacturers, and CAS numbers. It also discusses other indexing features like major focus terms mapped from MEDLINE, automatic indexing using Emtree terms, check tags for limits, and indexing of study types and topic terms. The document outlines the agenda which includes a history of indexing at Embase and a focus on in-depth drug, disease, and device indexing.
Embase: An introduction to indexing 20 October 2014Ann-Marie Roche
View our slides for an introduction to how indexing is carried out in Embase, guided examples of how indexing helps you to retrieve more comprehensive and relevant results and where you can find more information on indexing.
Embase for biomedical answers - Indexing - webinar - 21 Nov 2012Ann-Marie Roche
Our Embase expert, Ian Crowlesmith, showed us:
- The main indexing principles for Embase
- How Embase drug and disease indexing can optimize your searches and results.
Adverse Event Monitoring
• Identify relationships between drugs, diseases and devices and their associated events
• Use new filter options to search, visualize and export drug, device and disease-specific details
• Learn how new query language possibilities enable identification of specific drug- or device-related adverse events
Literature Management for Pharmacovigilance: Outsource or in-house solution? ...Ann-Marie Roche
Pharmaceutical companies are required to screen scientific literature on a regular basis and this comes with many challenges, such as handling large amounts of data, building search strings and integrating EMA MLM results. Out-sourcing literature screening to service providers reduces the workload for the PV-team, but how does it impact the literature management process overall? Maybe it results in decreased oversight and additional activities like audits and reconciliation? And what about building the search strategy?
During this webinar our PV expert, Dr. Joyce De Langen spoke about the following:
• The importance of literature management in Pharmacovigilance and the challenges.
• An evaluation of the benefits and risks of outsourcing literature management versus alternative solutions.
About the speaker:
Joyce de Langen, Ph.D has more than 10 years of experience in the domain of pharmacovigilance and drug safety. Through her work in the pharmaceutical industry, academia and regulatory authorities, Joyce has developed a broad perspective and knowledge in pharmacovigilance and drug safety.
Embase for pharmacovigilance: Search and validation March 22 2017Ann-Marie Roche
Scientific literature plays a critical role in Pharmacovigilance and Drug Safety workflows. Monitoring literature for mentions of adverse drug reactions (ADRs) is mandated by regulatory bodies, and marketing authorization holders (MAHs) that do not properly report ADRs can be subject to heavy fines. With an increasing volume of unstructured content to cover, along with rising labor costs, MAHs are looking for ways to make their literature monitoring more effective and efficient.
Abstract and indexing (A&I) databases play an important role in Literature Monitoring – due to the vast amount of scientific literature published daily – in order for MAH’s to locate specific articles or conference presentations that may be relevant for their products (for both benefit/risk analysis and ADR detection). Rather than reading all the literature, MAH’s create search strategies that identify the relevant records in A&I databases and execute the searches regularly. GVP module VI mandates that searches are done at least weekly, but many companies maintain a daily monitoring and review cycle.
In this webinar, Senior Product Development Manager Embase, Dr. Ivan Krstic discussed best practices for saving time, staying current, validating search strategies and mitigating risk in the face of these increasingly complex processes in literature monitoring
Embase: An introduction to indexing 20 October 2014Ann-Marie Roche
View our slides for an introduction to how indexing is carried out in Embase, guided examples of how indexing helps you to retrieve more comprehensive and relevant results and where you can find more information on indexing.
Embase for biomedical answers - Indexing - webinar - 21 Nov 2012Ann-Marie Roche
Our Embase expert, Ian Crowlesmith, showed us:
- The main indexing principles for Embase
- How Embase drug and disease indexing can optimize your searches and results.
Adverse Event Monitoring
• Identify relationships between drugs, diseases and devices and their associated events
• Use new filter options to search, visualize and export drug, device and disease-specific details
• Learn how new query language possibilities enable identification of specific drug- or device-related adverse events
Literature Management for Pharmacovigilance: Outsource or in-house solution? ...Ann-Marie Roche
Pharmaceutical companies are required to screen scientific literature on a regular basis and this comes with many challenges, such as handling large amounts of data, building search strings and integrating EMA MLM results. Out-sourcing literature screening to service providers reduces the workload for the PV-team, but how does it impact the literature management process overall? Maybe it results in decreased oversight and additional activities like audits and reconciliation? And what about building the search strategy?
During this webinar our PV expert, Dr. Joyce De Langen spoke about the following:
• The importance of literature management in Pharmacovigilance and the challenges.
• An evaluation of the benefits and risks of outsourcing literature management versus alternative solutions.
About the speaker:
Joyce de Langen, Ph.D has more than 10 years of experience in the domain of pharmacovigilance and drug safety. Through her work in the pharmaceutical industry, academia and regulatory authorities, Joyce has developed a broad perspective and knowledge in pharmacovigilance and drug safety.
Embase for pharmacovigilance: Search and validation March 22 2017Ann-Marie Roche
Scientific literature plays a critical role in Pharmacovigilance and Drug Safety workflows. Monitoring literature for mentions of adverse drug reactions (ADRs) is mandated by regulatory bodies, and marketing authorization holders (MAHs) that do not properly report ADRs can be subject to heavy fines. With an increasing volume of unstructured content to cover, along with rising labor costs, MAHs are looking for ways to make their literature monitoring more effective and efficient.
Abstract and indexing (A&I) databases play an important role in Literature Monitoring – due to the vast amount of scientific literature published daily – in order for MAH’s to locate specific articles or conference presentations that may be relevant for their products (for both benefit/risk analysis and ADR detection). Rather than reading all the literature, MAH’s create search strategies that identify the relevant records in A&I databases and execute the searches regularly. GVP module VI mandates that searches are done at least weekly, but many companies maintain a daily monitoring and review cycle.
In this webinar, Senior Product Development Manager Embase, Dr. Ivan Krstic discussed best practices for saving time, staying current, validating search strategies and mitigating risk in the face of these increasingly complex processes in literature monitoring
Literature monitoring for pharmacovigilance – outsourcing or in house solutionJulio dos Anjos
• A brief introduction about relevance of literature screening for P V.
• Challenges of literature screening in general.
• Benefits and risks of completely outsourcing literature screening for PV.
• Business case elements that need to take into consideration when deciding on outsourcing or in-sourcing PV literature screening.
In this presentation I have mentioned whatever the possible relevant content required for the title.
Citation Is done at the end of slide.
Content is up to date & true to my belief.
Thanks & Best Regards.
Anurag Pandey
B.Pharm (FACULTY OF PHARMACY, INVERTIS UNIVERSITY)
M.Pharm (INSTITUTE OF PHARMACY, NIRMA UNIVERSITY)
Email :- anurag.dmk05@gmail.com
Clinical data sharing: why publishing negative and less impactful results is ...Ann-Marie Roche
Clinical data sharing: why publishing negative and less impactful results is important for patient safety
Clinical trials are essential in drug development and are the cornerstone for getting a medicinal product authorized for marketing, because clinical trials investigate efficacy and drug safety. When the results of clinical trials are published, they can be informative to health care professionals, policy makers, media and the general public. But not all trial results are conclusive or significant, and many trials show that drugs are ineffective. These results often do not get published, either because these results are not suitable for a journal or because the researcher does not think these results are worth publishing. Due to the fact that inconclusive and insignificant results are not published, we are facing a publication bias towards positive results. During this webinar the speaker will demonstrate why publishing negative and less impactful results of clinical trials, as in Elsevier’s newly launched Open Access Journal ‘Contemporary Clinical Trials Communications’ reduces publication bias and is important for patient safety.
Anatomic Therapeutic Chemical Classification, Defined daily dose, Drug utilis...Dr.Amreen Saba Attariya
detailed information about Anatomic Therapeutic Chemical Classification, Defined daily dose, Drug utilisation, DU90%, WHO Collaborting Centre for drug statistic methodology, DDD/1000inhabitants/day, DDD/100beddays, DDD/1000inhabitants/year, Pediatric DDD, ATC & DDD in drug utilisation research, Electronic Prescribing, Guidelines for ATC classification & DDD assignment 2016
CFTCC
2015 Learning about the IND/IDE Process and Reimbursements for New Drugs and Devices
Erin O'Reilly, PhD, RAC
Assoc. Director, Regulatory Affairs
Translational Medicine Institute
Introduces the basics of filing an Investigational New Drug (IND) Application with the FDA
Prof. Boyce discusses the "Linked SPLs" system its relationship to SPLs stored in DailyMed and the OpenFDA initiative. The talk will focus on the potential uses, strengths, and limitations Linked SPLs which represents drug product labeling as Semantic Web Linked Data.
Video of this talk can be found at the link below starting at starts at 3:11:26: http://videocast.nih.gov/summary.asp?Live=14776&bhcp=1
21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTSPallavi Christeen
this presentation describes briefly about Bioavailability and Bioequivalence requirements as per US FDA Code of Federal Regulations under title 21 and chapter 320
1.Patients have poor or no knowledge of the price variations among branded and generic medicines, and leave the choice of the medicine to the doctor.
2.The government must take up generic promotional schemes, general awareness programs on quality of generics to build confidence among prescribers, pharmacists, and consumers.
Literature monitoring for pharmacovigilance – outsourcing or in house solutionJulio dos Anjos
• A brief introduction about relevance of literature screening for P V.
• Challenges of literature screening in general.
• Benefits and risks of completely outsourcing literature screening for PV.
• Business case elements that need to take into consideration when deciding on outsourcing or in-sourcing PV literature screening.
In this presentation I have mentioned whatever the possible relevant content required for the title.
Citation Is done at the end of slide.
Content is up to date & true to my belief.
Thanks & Best Regards.
Anurag Pandey
B.Pharm (FACULTY OF PHARMACY, INVERTIS UNIVERSITY)
M.Pharm (INSTITUTE OF PHARMACY, NIRMA UNIVERSITY)
Email :- anurag.dmk05@gmail.com
Clinical data sharing: why publishing negative and less impactful results is ...Ann-Marie Roche
Clinical data sharing: why publishing negative and less impactful results is important for patient safety
Clinical trials are essential in drug development and are the cornerstone for getting a medicinal product authorized for marketing, because clinical trials investigate efficacy and drug safety. When the results of clinical trials are published, they can be informative to health care professionals, policy makers, media and the general public. But not all trial results are conclusive or significant, and many trials show that drugs are ineffective. These results often do not get published, either because these results are not suitable for a journal or because the researcher does not think these results are worth publishing. Due to the fact that inconclusive and insignificant results are not published, we are facing a publication bias towards positive results. During this webinar the speaker will demonstrate why publishing negative and less impactful results of clinical trials, as in Elsevier’s newly launched Open Access Journal ‘Contemporary Clinical Trials Communications’ reduces publication bias and is important for patient safety.
Anatomic Therapeutic Chemical Classification, Defined daily dose, Drug utilis...Dr.Amreen Saba Attariya
detailed information about Anatomic Therapeutic Chemical Classification, Defined daily dose, Drug utilisation, DU90%, WHO Collaborting Centre for drug statistic methodology, DDD/1000inhabitants/day, DDD/100beddays, DDD/1000inhabitants/year, Pediatric DDD, ATC & DDD in drug utilisation research, Electronic Prescribing, Guidelines for ATC classification & DDD assignment 2016
CFTCC
2015 Learning about the IND/IDE Process and Reimbursements for New Drugs and Devices
Erin O'Reilly, PhD, RAC
Assoc. Director, Regulatory Affairs
Translational Medicine Institute
Introduces the basics of filing an Investigational New Drug (IND) Application with the FDA
Prof. Boyce discusses the "Linked SPLs" system its relationship to SPLs stored in DailyMed and the OpenFDA initiative. The talk will focus on the potential uses, strengths, and limitations Linked SPLs which represents drug product labeling as Semantic Web Linked Data.
Video of this talk can be found at the link below starting at starts at 3:11:26: http://videocast.nih.gov/summary.asp?Live=14776&bhcp=1
21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTSPallavi Christeen
this presentation describes briefly about Bioavailability and Bioequivalence requirements as per US FDA Code of Federal Regulations under title 21 and chapter 320
1.Patients have poor or no knowledge of the price variations among branded and generic medicines, and leave the choice of the medicine to the doctor.
2.The government must take up generic promotional schemes, general awareness programs on quality of generics to build confidence among prescribers, pharmacists, and consumers.
Review the building blocks of QUOSA’s literature sharing capabilities:
• Review best practices for capturing and manually curating literature for sharing with colleagues
• Customize your QUOSA RSS feeds by adding key information like products, diseases, and commentary as well as your organization’s branding
• Syndicate your sharing more widely by adding QUOSA “Dynamic Links” to SharePoint
Embase webinar Systematic searching with EmtreeAnn-Marie Roche
Our Embase expert Ian Crowlesmith covered:
•Summarize key Emtree enhancements made since January 2014
•Demonstrate many aspects of Emtree which are important to know for designing the most efficient searches in Embase
•Focus on additional indexing aspects such as candidate terms, searching for new drugs etc
Embase for biomedical answers: Content and coverage.23 may2012Ann-Marie Roche
During our 45-min webinar (including time for questions), our Embase expert, Ian Crowlesmith covered the following:
- Reviewed Embase content and article processing policies
- Compared journal coverage in Embase and MEDLINE and discussed how MEDLINE compliments Embase content
- Demonstrated how to best search for current content such as Articles in Press, In Process and conference abstracts.
Embase: Using Emtree to enhance your searching - 27 March 2013Ann-Marie Roche
In this webinar, Ian Crowlesmith reviewed the following:
- Emtree update policy, including backposting
- Recent enrichments in medical device terminology
- Optimizing retrieval using Emtree
COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS ASKED IN DRUG REGULATORY AFFAIRS ...Pristyn Research Solutions
THESE ARE SOME COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS ASKED IN DRUG REGULATORY AFFAIRS INTERVIEW
FOR ENROLLMENT CALL US ON - 9028839789
https://pristynresearch.com/
MAIL ID - pristynresearch@gmail.com
FACEBOOK- https://www.facebook.com/pristynsolutions
INSTAGRAM- https://www.instagram.com/pristyn_res...
TWITTER- https://twitter.com/Pristynresearch
SLIDESHARE- https://www.slideshare.net/azherkhan5916
LINKEDIN- https://www.linkedin.com/in/pristyn-research-191072119/
ADDRESS-
1) Parmar Trade Centre, A-wing,105/106, Sadhu Vaswani Chowk, Pune, 411001. Email: info@pristynresearch.com Phone: 09028839789
2)T-21/4 ,Opposite To Expert Global, Garware Stadium Road , Software Technology Park of India(STPI), MIDC, Aurangabad-431001. Email: info@pristynresearch.com Call us: 09607709586
How predictive models help Medicinal Chemists design better drugs_webinarAnn-Marie Roche
All scientific disciplines, including medicinal chemistry, are experiencing a revolution in unprecedented rates of data being generated and the subsequent analysis and exploitation of this data is increasingly fundamental to innovation. Using data to design better compounds is a challenge for Medicinal and Computational chemists.
The design of small-molecule drug candidates, encompassing characteristics such as potency, selectivity and ADMET (absorption, distribution, metabolism, excretion and toxicity) is a key factor in the success of clinical trials and computer-aided drug discovery/design methods have played a major role in the development of therapeutically important small molecules for over three decades. These methods are broadly classified as either structure-based or ligand-based.
In this webinar our expert Dr. Olivier Barberan will discuss ligand-based methods and he will cover the following:
How to use only ligand information to predict activity depending on its similarity/dissimilarity to previously known active ligands.
- Discuss ligand-based pharmacophores, molecular descriptors, and quantitative structure-activity relationships and important tools such as target/ligand databases necessary for successful implementation of various computer-aided drug discovery/design methods in a drug discovery campaign.
Webinar: New RMC - Your lead_optimization Solution June082017Ann-Marie Roche
The drug discovery landscape is rapidly changing and drives the need to generate leads with lower attrition rates.
In this webinar, our expert Dr. Olivier Barberan discussed how NEW Reaxys Medicinal chemistry in NEW Reaxys allows better discovery and exploration of structure activity relationship and also supports a more efficient property-based drug design approach. He covered the following:
• How has RMC being transformed into a more accessible tool for all users, allowing complex searches and workflows to be easily carried out.
• A demonstration of how more than ever RMC is the only lead-optimization solution you will need.
Oil&Gas Thought Leader Webinar - New Plays for Old Ideas - Dr.Gabor TariAnn-Marie Roche
In our April 2017 webinar, three industry experts shared their research and demonstrated the importance of focusing on fundamental geologic and geophysical research approaches that integrate variety of data, information and concepts from disparate sources and related disciplines.
This back-to-fundamentals research can both inspire and accelerate exploration teams’ thinking about petroleum systems and lead to a path to success.
Dr Gabor Tari is currently the Group Chief Geologist at OMV. He has over 20 years’ experience working in upstream oil & gas and has worked for Amoco, BP, and Vanco, before joining OMV in 2007. Gabor has worked on exploration projects in basins around the globe, including Romania, Angola, North Africa, and the Middle East. He has authored over 50 scientific publications, presented papers at dozens of conferences, and most recently co-authored the book Permo-Triassic Salt Provinces of Europe, North Africa and the Atlantic Margins, with Dr Joan Flinch (Repsol) and Juan Soto, Professor of Geodynamics in the Granada University and in the Instituto Andaluz de Ciencias de la Tierra, Spain, which is currently available from Elsevier for pre-order online.
Gabor discussed and shared some examples of how new plays can be built on a solid foundation of petroleum system development and research, and how new ideas can be garnered from building on published research of oil & gas companies, academia, service providers and consultants.
Oil&Gas Thought-Leader Webinar - New Plays for Old Ideas - Dr. Rob ForknerAnn-Marie Roche
In our April 2017 webinar, three industry experts shared their research and demonstrated the importance of focusing on fundamental geologic and geophysical research approaches that integrate variety of data, information and concepts from disparate sources and related disciplines. This back-to-fundamentals research can both inspire and accelerate exploration teams’ thinking about petroleum systems and lead to a path to success.
Dr Rob Forkner is a carbonate geologist at Statoil, working in the carbonate plays and reservoirs research group in Austin, Texas, focusing on carbonate play prediction in Atlantic margin systems. Prior to Statoil, Rob worked at Maersk and Shell in onshore and offshore in well planning, geosteering, high-resolution sequence stratigraphy and facies prediction, carbonate sedimentology in unconventional assets, evaporite classification and prediction, rock typing, and more recently, carbonate system suppression and recovery during Oceanic Anoxic Events.
Oil&Gas Thought-Leader Webinar - New Plays for Old Ideas - Dr. Sander HoubenAnn-Marie Roche
In our April 2017 webinar, three industry experts shared their research and demonstrated the importance of focusing on fundamental geologic and geophysical research approaches that integrate variety of data, information and concepts from disparate sources and related disciplines.
This back-to-fundamentals research can both inspire and accelerate exploration teams’ thinking about petroleum systems and lead to a path to success.
Dr. Sander Houben is a biostratrapher and researcher within the Basin Analysis team at TNO, Netherlands Organisation for Applied Scientific Research, and the leading research institute for applied sciences in the Netherlands. As part of the Basin Analysis Team, Sander provides scientific and technical expertise regarding stratigraphic and paleo-environmental constraints for multidisciplinary projects. In addition to conducting research, he leads TNO’s biostratigraphic consultancy research programs.
The All-New 2016 Engineering Academic Challenge - developed by students for students
The Engineering Academic Challenge (formerly as the Knovel Academic Challenge) is an immersive, 5-week interactive problem-set competition, featuring weekly thematic engineering challenges built around five transdisciplinary themes inspired by the National Academy of Engineering Grand Challenges.
Dr. Su Golder, NIHR Research Fellow at the University of York, presents findings from her recent publication: “Systematic review on the prevalence, frequency and comparative value of adverse events data in social media”.
Learn how to use Pathway Studio to explore biomarkers and brain regions. With the addition of highly sophisticated visualization tools, users can interactively explore the vast number of connections created to help unravel disease biology. In addition, an innovative new taxonomy based on brain region identifications will be presented. Together, these innovations can be applied to rapidly increase the knowledge of diseases based on published findings.
Cell centered database for immunology and cancer research feb252016Ann-Marie Roche
Determining the cellular mechanisms of diseases is a crucial requirement for understanding the causes and progression of diseases, predicting outcomes, and developing new treatments. Often relevant information, e.g. what cells are involved in a disease or what effects does a drug have on cells, is scattered across many papers and journals, which makes it difficult for researchers to be sure they have a complete picture. Using Elsevier’s automated text mining technology, we have created a new cell-centered database consisting of 850 000 facts captured from more than 24 million PubMed abstracts and 3.5 million full text articles for use in Pathway Studio. This database focused primarily on cellular aspects of immunology and immuno-oncology can be used to summarize and visualize published research, and to analyze experimental data.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
10. 10
drug of major focus (A term)
drug subheading
disease treated
adverse drug reactions
comparatordrug
route by which drug was
administered
other drug subheadings
DRUG TERMS AND SUBHEADINGS
11. 11
drug of major focus (A term)
drug subheading
disease treated
adverse drug reactions
comparatordrug
route by which drug was
administered
other drug subheadings
DRUG TERMS AND SUBHEADINGS
A aclidinium bromide
12. 12
drug of major focus (A term)
drug subheading
disease treated
adverse drug reactions
comparatordrug
route by which drug was
administered
other drug subheadings
DRUG TERMS AND SUBHEADINGS
A aclidinium bromide
drug therapy
chronic obstructive lung disease
13. 13
drug of major focus (A term)
drug subheading
disease treated
adverse drug reactions
comparatordrug
route by which drug was
administered
other drug subheadings
DRUG TERMS AND SUBHEADINGS
A aclidinium bromide
drug therapy
chronic obstructive lung disease
adverse drug reaction
coughing
diarrhea
ECG abnormality
headache
pruritus
rhinopharyngitis
tooth pain
14. 14
drug of major focus (A term)
drug subheading
disease treated
adverse drug reactions
comparatordrug
route by which drug was
administered
other drug subheadings
DRUG TERMS AND SUBHEADINGS
A aclidinium bromide
drug therapy
chronic obstructive lung disease
adverse drug reaction
coughing
diarrhea
ECG abnormality
headache
pruritus
rhinopharyngitis
tooth pain
drug comparison
formoterol fumarate
15. 15
drug of major focus (A term)
drug subheading
disease treated
adverse drug reactions
comparatordrug
route by which drug was
administered
other drug subheadings
DRUG TERMS AND SUBHEADINGS
A aclidinium bromide
drug therapy
chronic obstructive lung disease
adverse drug reaction
coughing
diarrhea
ECG abnormality
headache
pruritus
rhinopharyngitis
tooth pain
drug comparison
formoterol fumarate
(route of drug administration)
inhalational drug administration
16. 16
drug of major focus (A term)
drug subheading
disease treated
adverse drug reactions
comparatordrug
route by which drug was
administered
other drug subheadings
DRUG TERMS AND SUBHEADINGS
A aclidinium bromide
drug therapy
chronic obstructive lung disease
adverse drug reaction
coughing
diarrhea
ECG abnormality
headache
pruritus
rhinopharyngitis
tooth pain
drug comparison
formoterol fumarate
(route of drug administration)
inhalational drug administration
other subheadings
clinical trial
drug dose
17. 17
DRUG TERMS AND SUBHEADINGS
B formoterol fumarate
drug therapy
chronic obstructive lung disease
adverse drug reaction
coughing
diarrhea
headache
pruritus
rhinopharyngitis
tooth pain
drug comparison
aclidinium bromide
(route of drug administration)
inhalational drug administration
other subheadings
clinical trial
drug with minor focus (B term)
drug subheading
disease treated
adverse drug reactions
comparatordrug
route by which drug was
administered
other drug subheadings
18. 18
DISEASES AND OTHER TERMS
other check tags
minor focus (B) terms
study type check tags
sex and age check tags
disease subheading
disease with major focus (A)
human study type check tag
drugs treating disease
19. 19
other check tags
minor focus (B) terms
study type check tags
sex and age check tags
disease subheading
disease with major focus (A)
human study type check tag
drugs treating disease
DISEASES AND OTHER TERMS
A chronic obstructive lung disease
20. 20
other check tags
minor focus (B) terms
study type check tags
sex and age check tags
disease subheading
disease with major focus (A)
human study type check tag
drugs treating disease
DISEASES AND OTHER TERMS
A chronic obstructive lung disease
drug therapy
aclidinium bromide, formoterol*
21. 21
other check tags
minor focus (B) terms
study type check tags
sex and age check tags
disease subheading
disease with major focus (A)
human study type check tag
drugs treating disease
DISEASES AND OTHER TERMS
A chronic obstructive lung disease
drug therapy
aclidinium bromide, formoterol*
B randomized controlled trial
B controlled study
B crossover procedure
B double blind procedure
B phase 2 clinical trial
B multicenter study
22. 22
other check tags
minor focus (B) terms
study type check tags
sex and age check tags
disease subheading
disease with major focus (A)
human study type check tag
drugs treating disease
DISEASES AND OTHER TERMS
A chronic obstructive lung disease
drug therapy
aclidinium bromide, formoterol*
B randomized controlled trial
B controlled study
B crossover procedure
B double blind procedure
B phase 2 clinical trial
B multicenter study
B major clinical study
23. 23
other check tags
minor focus (B) terms
study type check tags
sex and age check tags
disease subheading
disease with major focus (A)
human study type check tag
drugs treating disease
DISEASES AND OTHER TERMS
A chronic obstructive lung disease
drug therapy
aclidinium bromide, formoterol*
B randomized controlled trial
B controlled study
B crossover procedure
B double blind procedure
B phase 2 clinical trial
B multicenter study
B major clinical study
B adult
B female
B male
B human
24. 24
other check tags
minor focus (B) terms
study type check tags
sex and age check tags
disease subheading
disease with major focus (A)
human study type check tag
drugs treating disease
DISEASES AND OTHER TERMS
A chronic obstructive lung disease
drug therapy
aclidinium bromide, formoterol*
B randomized controlled trial
B controlled study
B crossover procedure
B double blind procedure
B phase 2 clinical trial
B multicenter study
B major clinical study
B adult
B female
B male
B human
B bronchodilatation
B forced expiratory volume
B forced vital capacity
B powder inhaler
B drug dose comparison
B evening dosage
B morning dosage
25. 25
DEVICE TRADE NAMES WITH LINKED
MANUFACTURER NAMES
drug trade name & drug manufacturer
name & country code
clinical trial number repository & clinical
trial number
device trade name & device
manufacturer name & country code (for
2 devices)
CLINICAL TRIAL NUMBERS
DRUG TRADE NAMES WITH LINKED
MANUFACTURER NAMES
26. 26
DRUG TRADE NAMES WITH LINKED
MANUFACTURER NAMES
foradil
Novartis CHE
DEVICE TRADE NAMES WITH LINKED
MANUFACTURER NAMES
drug trade name & drug manufacturer
name & country code
clinical trial number repository & clinical
trial number
device trade name & device
manufacturer name & country code (for
2 devices)
CLINICAL TRIAL NUMBERS
27. 27
DEVICE TRADE NAMES WITH LINKED
MANUFACTURER NAMES
DRUG TRADE NAMES WITH LINKED
MANUFACTURER NAMES
foradil
Novartis CHE
Genuair
Almirall ESP
Aerolizer
Novartis CHE
drug trade name & drug manufacturer
name & country code
clinical trial number repository & clinical
trial number
device trade name & device
manufacturer name & country code (for
2 devices)
CLINICAL TRIAL NUMBERS
28. 28
CLINICAL TRIAL NUMBERS
DRUG TRADE NAMES WITH LINKED
MANUFACTURER NAMES
foradil
Novartis CHE
DEVICE TRADE NAMES WITH LINKED
MANUFACTURER NAMES
Genuair
Almirall ESP
Aerolizer
Novartis CHE
drug trade name & drug manufacturer
name & country code
clinical trial number repository & clinical
trial number
device trade name & device
manufacturer name & country code (for
2 devices)
ClinicalTrials.gov
NCT01120093
30. 30
Embase indexing principles
1. TRANSLATE
To bring the semantic richness of medical terminology
within your grasp: mapping many synonyms to a single
(natural language) preferred terminology
2. EXPAND
To expose and summarize the information in biomedical
articles beyond title and abstract: discovering in-depth
data about drugs, diseases and medical devices
3. FOCUS
To identify the key concepts hidden within those articles –
what they are really about – providing you with a toolkit to
find answers beginning with comprehensive searches
31. 31
Embase history of indexing
Excerpta
Medica
1947 1963
Controlled
vocabulary
2
1
Emtree +
subheadings
1987
3
Item
types
1990
4
RCTs
Additional
check tags
1993
5 Automatic
indexing
2009
6
Medical
devices
2012
7
Searchable
triple
indexing
2015
8
1
2
3
4
5
6
7
8
First 9 independent abstract journals with natural language indexing
Indexing unified into a controlled vocabulary, with synonyms
Tree structure added based on MeSH: birth of Emtree
Introduction of 8 item types (aka publication types)
Extension of check tags with the first of several new EBM terms
Conference abstracts & In-process records automatically indexed
Addition of >3000 new medical device terms + 4 new subheadings
Searchable triple indexing introduced for 5 drug triples + 2 device triples
32. 32
Embase indexing: the video
Ref: http://www.elsevier.com/solutions/embase-biomedical-research
33. 33
Drugs & diseases1: in-depth indexing
Embase Indexing Guide, section 5.3.3
“Drug terms are index terms used for all drugs and chemicals: not only
therapeutic drugs, but also endogenous compounds, laboratory chemicals
and environmental chemicals or toxins. It is important to realise that “drugs”
as described in Embase may refer to any chemical entity.”
All significant mentions are indexed *
New drugs as candidate terms *
CAS registry numbers generated
All generic drug names in Emtree
Emtree updated 3x per year *
Indexed with subheadings *
Key subheadings indexed as triples
Drug trade names also indexed
Also drug manufacturer names
1 and (since 2014) also devices * applies to disease terms as well as drugs
New drugs as candidate terms
34. 34
Using Emtree to find new drugs
Reference: http://www.news-sentinel.com/apps/pbcs.dll/article?AID=/20121115/NEWS/121119726/-1/LIVING
48. 48
| 48
• Dissection of an Embase index
• A brief history of indexing at Embase
• Focusing on drugs: in-depth indexing
- drugs, diseases and devices
- subheadings (including floating subheadings & triple links)
- trade names, manufacturers
- CAS numbers
• Other indexing highlights
- major focus terms - mapping from MEDLINE
- Emtree / backposting - automatic indexing
- check tags & limits - medical devices
- study types & topic terms - numerical indexing
Agenda: what have we covered so far?
Reference: Embase Indexing guide
See:http://www.elsevier.com/__data/assets/pdf_file/0016/92104/Embase-indexing-guide-2015.pdf
59. 59
Check tags
Embase Indexing Guide, section 5.3.2 & Appendix 2
“Check tags … represent a special group of general terms whose definitions
are described by scope notes, and which are assigned by indexers using a
check list to ensure the highest possible consistency of indexing.”
Category Examples
Item types article, review, letter, editorial,conference abstract
Human study
types
human, major clinicalstudy, case report, human experiment,
human cell
Animal study
types
nonhuman,animalmodel, animalexperiment, animalcell
Sex and age male, female, newborn, child, adolescent,adult, aged
Clinical trials &
EBM
randomized controlledtrial, meta analysis, doubleblind
procedure, systematic review, diagnostic test accuracy study
63. 63
Searching for animal studies
humans animals
humans
AND
animals
neither humans nor animals
64. 64
Searching for animal studies
[humans]/lim [animals]/lim
[humans/lim
AND
[animals]/lim
NOT ([humans]/lim OR [animals]/lim)
To search for animals only:
[animals]/lim NOT [humans]/lim
65. 65
Searching for animal studies
animal:de
OR
invertebrate'/exp OR 'amphibia'/exp OR 'fish'/exp OR 'boreoeutheria'/exp OR 'afrotheria'/exp OR
'dermoptera'/exp OR 'glires'/exp OR 'scandentia'/exp OR 'sauropsid'/exp OR 'laurasiatheria'/exp OR
'ungulate'/exp OR 'reptile'/exp OR 'cercopithecidae'/exp OR 'marsupial'/exp OR 'monotremate'/exp OR
'prosimian'/exp OR 'tarsiiform'/exp OR 'hylobatidae'/exp OR 'xenarthra'/exp OR 'platyrrhini'/exp OR
'chimpanzee'/exp OR 'gorilla'/exp OR 'homo neanderthalensis'/exp OR 'cephalochordata'/exp OR
'hyperotreti'/exp OR 'urochordata'/exp OR 'ambulacraria'/exp OR 'coelomata'/exp OR
'protostomia'/exp OR 'pseudocoelomata'/exp OR 'coelenterate'/exp OR 'mesozoa'/exp OR
'placozoa'/exp OR 'porifera'/exp OR 'juvenile animal'/exp OR 'male animal'/exp OR 'female
animal'/exp
OR
primate'/de OR 'haplorhini'/de OR 'mammal'/de OR 'catarrhini'/de OR 'simian'/de OR 'ape'/de OR
'amniote'/de OR 'tetrapod'/de OR 'vertebrate'/de OR 'chordata'/de OR 'deuterostomia'/de OR
'bilateria'/de OR 'therian'/de OR 'hominid'/de OR 'euarchontoglires'/de OR 'placental mammals'/de
This is how the limit is constructed:
Do NOT use: ‘animal’/exp as this includes humans !!!
67. 67
Study types and topic terms
From Emtree facet “Types of article or study”
Include many more terms than check tags
As from 2011: including “Topic terms”
Topic terms: 10 terms ending with (topic)
Topic terms were introduced in 2011 to differentiate
between study types indexed when the article is the
primary report for an RCT (for example), and articles in
which that term is only a topic that is discussed.
68. 68
MEDLINE records in Embase
• Almost 9m records in Embase are licensed from NLM
• MeSH terms from these records are mapped to Emtree
• See the White Paper: Coverage of MEDLINE in Embase
“When MeSH terms are mapped to
Emtree, subheadings are mapped
to Embase subheadings.
Since not all MeSH subheadings
have an exact Emtree equivalent,
some of them generate Emtree
terms rather than subheadings.”
73. 73
Automatic indexing in Embase
When do we index automatically?
1. When data is limited to TI, AB
(conference abstracts)
2. When data is provisional
(articles in press, in process records)
How is it done?
1. Term recognition
(e.g. mapping of synonyms => PTs)
2. Morphological variants
(e.g. plural => singular )
2. Term-specific rules
(e.g. for “human”)
Not included:
• subheadings
• candidate terms
74. 74
Medical devices
Emtree coverage expanded from 900 devices (in 2012) to over 3000 devices (in 2015)
Medical devices have been indexed in over 2 million records in Embase (1947-2015)
Four new subheadings (incl. two with triple links) were introduced for devices in 2014
80. 80
Embase Indexing and Retrieval: Summary
Translate Expand Focus
Every record in Embase is indexed to help you identify the
records you need to find biomedical answers.
Embase indexing focuses on drugs, diseases and (medical)
devices: these concepts are indexed in-depth.
Essential support is provided by tools such as Emtree back-
posting, check tags, major focus terms and numerical indexing.
81. 81
| 81
• Q&A will be sent to you by email and for more information and
questions please contact your regional office
• Please click on at Embase.com for Embase training materials,
including recordings of all archived webinars from 2014 and 2015
Thank you!
Please fill out the survey that appears on your
screen after leaving the webinar.
82. 82
Embase for biomedical
searching: Indexing
and retrieval
Dr. Ian Crowlesmith
Senior Product Manager for Content Development
October 28, 2015
Thank you for
your attention